Retinoids in Cancer Chemoprevention

Current Cancer Drug Targets

Volumn 4, Issue 3, 2004, Pages 285-298

  Okuno, Masataka ^a   Kojima, Soichi ^b   Matsushima Nishiwaki, Rie ^a   Tsurumi, Hisashi ^a   Muto, Yasutoshi ^c   Friedman, Scott L ^d   Moriwaki, Hisataka ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b RIKEN   (Japan)

^c SUGIYAMA JOGAKUEN UNIVERSITY   (Japan)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

14 HYDROXYRETRORETINOL; 9,13 DICIS RETINOIC ACID; ACYLIC RETINOID; ALITRETINOIN; ALPHA INTERFERON; ALPHA TOCOPHEROL; ARSENIC TRIOXIDE; BETA INTERFERON; GLYCYRRHIZIC ACID; HEPATITIS B VACCINE; HERBACEOUS AGENT; ISOTRETINOIN; NIK 333; POLYPRENOIC ACID; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID; RETINOID DERIVATIVE; RETINOID X RECEPTOR; RETINOL DERIVATIVE; RETINOL ESTER; TAMIBAROTENE; TAMOXIFEN; UNCLASSIFIED DRUG; XIAO CHAI HU TANG;

ADULT; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; CELL DIFFERENTIATION; CELL MATURATION; CELL TRANSFORMATION; CHEMOPROPHYLAXIS; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; FEMALE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HOT FLUSH; HUMAN; IMMUNOLOGICAL TOLERANCE; LEUKEMIA CELL; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MENSTRUAL IRREGULARITY; MOUTH CANCER; NEUTROPHIL; PRECANCER; PROMYELOCYTE; PROMYELOCYTIC LEUKEMIA; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; REMISSION; REVIEW; SKIN CANCER; VAGINAL DRYNESS;

ANIMALS; ANTICARCINOGENIC AGENTS; HUMANS; NEOPLASMS; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; RETINOIDS; TRANSCRIPTION FACTORS;

EID: 2342430666     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043333023     Document Type: Review

References (85)

1. Hansen, L. A.; Sigman, C. C.; Andreola, F.; Ross, S. A.; Kelloff, G. J.; De Luca, L. M. Retinoids in Chemoprevention and Differentiation Therapy. Carcinogenesis 2000, 21, 1271-1279.
2. Moon, R. C.; Metha, R. G.; Rao, K. V. N. In: The Retinoids: Biology, Chemistry, and Medicine, 2nd Ed: Retinoids and Cancer in Experimental Animals; Sporn, M. B.; Roberts, A. B.; Goodman, D. S. Eds.; Raven Press: New York, NY, 1994, pp. 573-595.
3. Hong, W. K.; Itri, L. M. In: The Retinoids: Biology, Chemistry, and Medicine, 2nd Ed.: Retinoids and Human Cancer; Sporn, M.B.; Roberts, A. B.; Goodman, D. S. Eds.; Raven Press: New York, NY, 1994, pp. 597-630.
4. Lippman, S. M.; Lotan, R. Advances in The Development of Retinoids as Chemopreventive Agents. J. Nutr. 2000, 130, 497S-482S.
5. Sun, S.-Y.; Lotan, R. Retinoids and Their Receptors in Cancer Development and Chemoprevention. Critical Rev. Oncol./Hematol. 2002, 41, 41-55.
6. Blaner, W. S.; Olson, J. A. In: The Retinoids: Biology, Chemistry, and Medicine, 2nd Ed.: Retinol and Retinoic Acid Metabolism; Sporn, M.B.; Roberts, A.B.; Goodman, D.S. Eds.; Raven Press: New York, NY, 1994, pp. 229-255.
7. Blomhoff, R.; Wake, K. Perisinusoidal Stellate Cells of The Liver: Important Roles in Retinol Metabolism and Fibrosis. FASEB J. 1991, 5, 271-277.
8. Mangelsdorf, D. J.; Umesono, K.; Evans, R. M. In: The Retinoids: Biology, Chemistry, and Medicine, 2nd Ed.: The Retinoid Receptors; Sporn, M.B.; Roberts, A.B.; Goodman, D.S. Eds.; Raven Press: New York, NY, 1994, pp. 319-349.
9. Huang, M.-E.; Yu-Chen, Y.; Shu-Rong, C.; Lu, M.-X.; Zhao, L.; Gu, L.-J.; Wang, Z.-Y. Use of All-trans Retinoic Acid in The Treatment of Acute Promyelocytic Leukemia. Blood 1988, 72, 567-572.
10. Okuno, M.; Sato, T.; Kitamoto, T.; Imai, S.; Kawada, N.; Suzuki, Y.; Yoshimura, H.; Moriwaki, H.; Onuki, K.; Masushige, S.; Muto, Y.; Friedman, S.L. ; Kato, S.; Kojima, S. Increased 9,13-di-cis Retinoic Acid in Rat Hepatic Fibrosis: Implication for a Potential Link between Retinoid Loss and TGF-β Mediated Fibrogenesis In Vivo. J. Hepatol. 1999, 30, 1073-1080.
11. Altucci, L.; Gronemeyer, H. The Promise of Retinoids to Fight against Cancer. Nat. Review Cancer 2001, 1, 181-193.
12. Hong, W.K.; Endicott, J.; Itri, L.M.; Doos, W.; Bastakis, J.G.; Bell, R. ; Fofonoff, S.; Byers, R.; Atkinson, F.N.; Vaughan, C.; Toth, B.B.; Kramer, A.; Dimery, I.W.; Skipper, S.; Strong, S. 13-cis-Retinoic Acid in The Treatment of Oral Leukoplakia. N. Engl. J. Med. 1986, 315, 1501-1505.
13. Shin, D. M.; Xu, X. C.; Lippman, S. M.; Lee, J. J.; Batsakis, J. D.; Ro, J. Y.; Martin, J. W.; Hittelman, W. N.; Lotan, R.; Hong, W. K. Accumulation of p53 Protein and Retinoic Acid Receptor-β in Retinoid Chemoprevention. Clin. Cancer Res. 1997, 3, 875-880.
14. Hong, W. K.; Lippman, S. M.; Itri, L. M.; Karp, D. D.; Lee, J. S.; Byers, R. M.; Schantz, S. P.; Kramer, A. M.; Lotan, R.; Peters, L. J.; Dimery, I. W.; Brown, B. W.; Goepfert, H. Prevention of Second Primary Tumors with Isotretinoin in Squamous-cell Carcinoma of The Head and Neck. N. Engl. J. Med. 1990, 323, 795-801.
15. Benner, S. E.; Pajak, T. F.; Lippman, S.M.; Earley, C.; Hong, W.K. Prevention of Second Primary Tumors with Isotretinoin in Patients with Squamous Cell Carcinoma of The Head and Neck: Long-term Follow-up. J. Natl. Cancer Inst. 1994, 86, 140-141.
16. Shin, D. M.; Khuri, F. R.; Murphy, B.; Garden, A. S.; Claymen, G.; Francisco, M.; Liu, D.; Glisson, B. S.; Ginsberg, L.; Papadimitrakopoulou, V.; Myers, J.; Morrison, W.; Gillenwater, A.; Ang, K. K.; Lippman, S. M.; Geopfert, H.; Hong, W. K. Combined Interferon-α, 13-cis-Retinoic Acid, and α-Tocopherol in Locally Advanced Head and Neck Squamous Cell Carcinoma: Novel Bioadjuvant Phase II Trial. J. Clin. Oncol. 2001, 19, 3010-3017.
17. Early Breast Cancer Trialists' Collaborative Group. Systemic Treatment of Early Breast Cancer by Hormone, Cytotoxic or Immune Therapy: 133 Randomized Trials Involving 31,000 Recurrences and 24,000 Deaths among 75,000 Women. Lancet 1992, 339, 1-15.
18. Camerini, T.; Mariani, L.; De Palo, G.; Marubini, L.; Di Mauro, M.G.; Decensi, A.; Costa, A.; Veronesi, U. Safety of The Synthetic Retinoid Fenretinide: Long-term Results from A Controlled Clinical Trial for The Prevention of Contralateral Breast Cancer. J. Clin. Oncol. 2001, 19, 1664-1670.
19. Kraemer, K. H.; DiGiovanna, J. J.; Moshell, A. N.; Tarone, R. E.; Peck, G. L. Previous Skin Cancer in Xeroderma Pigmentosum with The Use of Oral Etretinate. N. Engl. J. Med. 1988, 318, 1633-1637.
20. Warrell, R. P. Jr. Pathogenesis and Management of Acute Promyelocytic Leukemia. Annu. Rev. Med. 1996, 47, 555-565.
21. Lo Coco, F.; Nervi, C.; Avvisati, G.; Mandelli, F. Acute Promyelocytic Leukemia; A Curative Disease. Leukemia 1998, 12, 1866-1880.
22. de The, H.; Chomienne, C.; Lanotte, M.; Dego, L.; Dejean, A. The t(15;17) Translocation of Acute Promyelocytic Leukemia Fuses The Retinoic Acid Receptor α Gene to A Novel Transcribed Locus. Nature 1990, 347, 558-561.
23. Kakizuka, A.; Miller, W. H. Jr.; Umesono, K.; Warrell, R. P. Jr.; Frankel, S. R.; Murty, V. V. V. S.; Dmitrovsky, E.; Evans, R.M. Chromosomal Translocation t(15;17) in Human Acute Promyelocytic Leukemia Fuses RAR-α with A Novel Putative Transcription Factor, PML. Cell 1991, 66, 663-674.
24. de The, H.; Lavau, C.; Marchio, A.; Chomienne, C.; Degos, L.; Dejean, A. The PML-RARα Fusion mRNA Generated by The t(15;17) Translocation in Acute Promyelocytic Leukemia Encodes A Functionally Altered RAR. Cell 1991, 66, 675-684.
25. Kastner, P.; Perez, A.; Lutz, Y.; Rochette-Egly, C.; Gaub, M.P.; Durand, B.; Lanotte, M.; Berger, R.; Chambon, P. Structure, Localization and Transcriptional Properties of Two Classes of Retinoic Acid Receptor α Fusion Proteins in Acute Promyelocytic Leukemia (APL): Structural Similarities with A New Family of Oncoproteins. EMBO. J. 1992, 11, 629-642.
26. Grisolano, J. L.; Wesselschmidt, R. L.; Pelicci, P. G.; Ley, T. J. Altered Myeloid Development and Acute Leukemia in Transgenic Mice Expressing PML-RAR Alpha under Control of Cathepsin G Regulatory Sequences. Blood 1997, 89, 376-387.
27. Brown, D.; Kogan, S.; Lagasse, E.; Weissman, I.; Alcalay, M.; Pelicci, P.G.; Atwater, S.; Bishop, J.M. A PMLRARalpha Transgene Initiates Murine Acute Promyelocytic Leukemia. Proc. Natl. Acad. Sci. USA. 1997, 94, 2551-2556.
28. Grignani, F.; De Matteis, S.; Nervi, C.; Tomassoni, L.; Gelmetti, V.; Cioce, M.; Fanelli, M.; Ruthardt, M.; Ferrara, F.F.; Zamir, I.; Seiser, C.; Lazar, M.A.; Minucci, S.; Pelicci, P.G. Fusion Protein of The Retinoic Acid Receptor-α Recruit Histone Deacetylase in Promyelocytic Leukemia. Nature 1998, 319, 815-818.
29. Quignon, F.; De Bels, F.; Koken, M.; Feunteun, J.; Ameisen, J.C.; de The, H. PML Induces A Novel Caspase-independent Death Process. Nature Genet. 1998, 20, 259-265.
30. Wang, Z. G.; Ruggero, D.; Ronchetti, S.; Zhong, S.; Gaboli, M.; Rivi, R. ; Pandolfi, P. P. PML Is Essential for Multiple Apoptotic Pathways. Nature Genet. 1998, 20, 266-272.
31. Nelson-Burchenal, K.; Takle, J.; Pace, U.; Flynn, S.; Allopenna, J.; Martin, P.; George, S. T.; Goldberg, A. R.; Dmitrovsky, E. Targeting PML/RAR Alpha Translocation Product Triggers Apoptosis in Promyelocytic Leukemia Cells. Oncogene 1998, 17, 1759-1768.
32. Warrell, R. P. Jr.; de The, H.; Wang, Z. Y.; Degos, L. Acute Promyelocytic Leukemia. N. Engl. J. Med. 1993, 329, 177-189.
33. Degos, L.; Dombret, H.; Chomienne, C.; Daniel, M. T.; Miclea, J. M.; Chastang, C.; Castaigne, S.; Fenaux, P. All-trans-retinoic Acid as A Differentiating Agent in The Treatment of Acute Promyelocytic Leukemia. Blood 1995, 85, 2643-2653.
34. Chen, Z. X.; Xue, Y.Q.; Zhang, R.; Tao, R. F.; Xia, X. M.; Li, C.; Wang, W.; Zu, W. Y.; Yao, X. Z.; Ling, B. J. A Clinical and Experimental Study on All-trans Retinoic Acid-treated Acute Promyelocytic Leukemia Patients. Blood 1991, 78, 1413-1419.
35. Tobita, C.; Takeshita, A.; Kitamura, K.; Ohnishi, K.; Yanagi, M.; Hiraoka, A.; Karasuno, T.; Takeuchi, M.; Miyawaki, S.; Ueda, R.; Naoe, T.; Ohno, R. Treatment with A New Synthetic Reinoid, Am 80, of Acute Promyelocytic Leukemia Relapsed from Complete Remission Induced by All-trans Retinoic Acid. Blood 1997, 90, 967-973.
36. Soignet, S. L.; Maslak, P.; Wang, Z. G.; Jhanwar, S.; Calleja, E.; Dardashti, L. J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D. A.; Pandolfi, P. P.; Warrell, R. P. Jr. Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. N. Engl. J. Med. 1998, 339, 1341-1348.
37. 3) in The Treatment of Acute Promyelocytic Leukemia (APL): II. Clinical Efficacy and Pharmacokinetics in Relapsed Patients. Blood 1997, 89, 3354-3360.
38. Kiyosawa, K. Characteristics of Liver Cancer in Japan in Comparison with Liver Cancer in Foreign Countries. Hepatol. Res. 2002, 24, S4-S10.
39. El-Sarag, H. B.; Manson, A. C. Rising Incidence of Hepatocellular Carcinoma in The United States. N. Engl. J. Med. 1999, 340, 745-750.
40. Taylor-Robinson, S. D.; Foster, G. R.; Afora, S.; Hargreaves, S.; Thomas, H. C. Increase in Primary Liver Cancer in The UK, 1979-94. Lancet 1997, 350, 1142-1143.
41. Deuffic, S.; Poynard, T.; Buffat, L.; Valleron, A.-J. Trends in Primary Liver Cancer. Lancet 1998, 351, 214-215.
42. Shiratori, Y.; Yoshida, H.; Omata, M. Different Clinicophathological Features of Hepatocellular Carcinoma in Relation to Causative Agents. J. Gastroenterol. 2001, 36, 73-78.
43. Ikeda, K.; Saitoh, H.; Koida, I.; Arase, Y.; Tsubota, A.; Chayama, K.; Kumada, H.; Kawanishi, M. A Multivariate Analysis of Risk Factors of Hepatocellular Carcinogenesis: A Prospective Observation of 795 Patients with Viral and Alcoholic Cirrhosis. Hepatology 1993, 18, 47-53.
44. Adachi, E.; Maeda, T.; Matsumura, T.; Shirabe, K.; Kinukawa, N.; Sugimachi, K.; Tsuneyoshi, M. Risk Factors for Intrahepatic Recurrence in Human Small Hepatocellular Carcinoma. Gastroenterology 1995, 108, 768-775.
45. Kumada, T.; Nakano, S.; Takeda, I.; Sugiyama, K.; Osada, T.; Kiriyama, S.; Sone, Y.; Toyoda, H.; Shimada, S.; Takahashi, M.; Sassa, T. Patterns of Recurrence after Initial Treatment in Patients with Small Hepatocellular Carcinoma. Hepatology 1997, 25, 87-92.
46. Koda, M.; Murawaki, Y.; Mitsuda, A.; Ohyama, K.; Horie, Y.; Suou, T.; Kawasaki, H.; Ikawa, S. Predictive Factors for Intrahepatic Recurrence after Percutaneous Ethanol Injection Therapy for Small Hepatocellular Carcinoma. Cancer 2000, 88, 529-537.
47. Okada, S.; Shimada, K.; Yamamoto, J.; Takayama, T.; Kosuge, T.; Yamasaki, S.; Sakamoto, M.; Hirohashi, S. Predictive Factors for Postoperative Recurrence of Hepatocellular Carcinoma. Gastroenterology 1994, 106, 1618-1624.
48. Chen, Y.-J.; Yeh, S.-W.; Chen, J.-T.; Wu, C.-C.; Hsu, M.-T.; Tsai, S.-F. ; Chen, P.-J.; Lin, C.-H. Choromosomal Changes and Clonality Relationship between Primary and Recurrent Hepatocellular Carcinoma. Gastroenterology 2000, 119, 431-440.
49. Liver Cancer Study Group of Japan. Survey and Follow-up Study of Primary Liver Cancer in Japan. Acta Hepatol. Jpn. 1997, 38, 317-330 (in Japanese with English abstract).
50. Kakumu, S. Trends in Liver Cancer Researched by The Liver Cancer Study Group of Japan. Hepatol. Res. 2002, 24, S21-S27.
51. Chang, M.-H.; Chen, C.-J.; Lai, M.-S.; Hsu, H.-M.; Wu, T.-C.; Kong, M.-S.; Liang, D.-C.; Shau, W.-Y.; Chen, D.-S. Universal Hepatitis B Vaccination in Taiwan and The Incidence of Hepatocellular Carcinoma in Children. N. Engl. J. Med. 1997, 336, 1855-1859.
52. Nishiguchi, S.; Kuroki, T.; Nakatani, S.; Horimoto, H.; Takeda, T.; Nakajima, S.; Shiomi, S.; Seki, S.; Kobayashi, K.; Tango, T. Randomized Trial of Effects of Interferon-alpha on The Incidence of Hepatocellular Carcinoma in Chronic Active Hepatitis C with Cirrhosis. Lancet 1995, 346, 1051-1055.
53. International Interferon-alfa HCC Study Group. Effect of Interferon-alfa on Progression of Cirrhosis to Hepatocellular Carcinoma: A Retrospective Cohort Study. Lancet 1998, 351, 1535-1359.
54. Kasahara, A.; Hayashi, N.; Mochizuki, K.; Takayanagi, M.; Yoshioka, K.; Kakumu, S.; Iijima, A.; Urushihara, A.; Kiyosawa, K.; Okuda, M.; Hino, K.; Okita, K.; Osaka Liver Disease Study Group. Risk Factors for Hepatocellular Carcinoma and Its Incidence after Interferon Treatment in Patients with Chronic Hepatitis C. Hepatology 1998, 27, 1394-1402.
55. Yoshida, H.; Shiratori, Y.; Moriyama, M.; Arakawa, Y.; Ide, T.; Sata, M. ; Inoue, O.; Yano, M.; Tanaka, M.; Fujiyama, M.; Nishiguchi, S.; Kuroki, T.; Imazeki, F.; Yokosuka, O.; Kinoyama, S.; Yamada, G.; Omata, M. Interferon Therapy Reduces The Risk for Hepatocellular Carcinoma: National Surveillance Program of Cirrhotic and Noncirrhotic Patients with Chronic Hepatitis C in Japan. Ann. Intern. Med. 1999, 131, 174-181.
56. Oka, H.; Yamamoto, S.; Kuroki, T.; Harihara, S.; Marumo, T.; Kim, S.R.; Monna, T.; Kobayashi, K.; Tango, T. Prospective Study of Chemoprevention of Hepatocellular Carcinoma with Shosaiko-to (TJ-9). Cancer 1995, 76, 743-749.
57. Arase, Y.; Ikeda, K.; Murashima, N.; Chayama, K.; Tsubota, A.; Koida, I. ; Suzuki, Y.; Saitoh, S.; Kobayashi, M.; Kumada, H. The Long Term Efficacy of Glycyrrhizin in Chronic Hepatitis C Patients. Cancer 1997, 79, 1494-1500.
58. Muto, Y.; Moriwaki, H.; Ninomiya, M.; Adachi, S.; Saito, A.; Takasaki, K.T.; Tanaka, T.; Tsurumi, K.; Okuno, M.; Tomita, E.; Nakamura, T.; Kojima, T. Prevention of Second Primary Tumors by An Acyclic Retinoid, Polyprenoic acid, in Patients with Hepatocellular Carcinoma. N. Engl. J. Med. 1996, 334, 1561-1567.
59. Muto, Y.; Moriwaki H.; Saito, A. Prevention of Second Primary Tumors by An Acyclic Retinoid in Patients with Hepatocellular Carcinoma. N. Engl. J. Med. 1999, 340, 1046-1047.
60. Okuno, M.; Kojima, S.; Moriwaki, H. Chemoprevention of Hepatocellular Carcinoma: Concept, Progress and Perspectives. J. Gastroenterol. Hepatol. 2001, 16, 1329-1335.
61. Gutterman, J.U. Cytokine Therapeutics: Lessons from Interferon Alpha. Proc. Natl. Acad. Sci. USA. 1994, 91, 1198-1205.
62. Shiratori, Y.; Kato, N.; Yokosuka, O.; Imazeki, F.; Hashimoto, E.; Hayashi, N.; Nakamura, A.; Asada, M.; Kuroda, H.; Tanaka, N.; Arakawa, Y.; Omata, M. for The Tokyo-Chiba Hepatitis Research Group. Predictors of The Efficacy of Interferon Therapy in Chronic Hepatitis C Virus Infection. Gastroenterology 1997, 113, 558-566.
63. Muto, Y.; Moriwaki, H. Antitumor Activities of Vitamin A and Its Derivatives. J. Natl. Cancer Inst. 1984, 73, 1389-1393.
64. Moriwaki, H.; Muto, Y.; Ninomiya, M.; Kawai, K.; Suzuki, Y.; Seto, T. Inhibitory Effects of Synthetic Acidic Retinoid and Polyprenoic Acid on The Development of Hepatoma in Rats Induced by 3′ -Methyl-N,N-dimethyl-4-aminoazobenzene. J. Gastroenterol. 1988, 23, 546-552.
65. Nakamura, N.; Shidoji, Y.; Yamada, Y.; Hatakeyama, H.; Moriwaki, H.; Muto, Y. Induction of Apoptosis by Acyclic Retinoid in The Human Hepatoma-derived Cell Line, HuH-7. Biochem. Biophys. Res. Commun. 1995, 207, 382-388.
66. Yasuda, I.; Shiratori, Y.; Adachi, S.; Obora, A.; Takemura, M.; Okuno, M.; Shidoji, Y.; Seishima, M.; Muto, Y.; Moriwaki, H. Acyclic Retinoid Induces Partial Differentiation, Down-regulates Telomerase Reverse Transcriptase mRNA Expression and Telomerase Activity, and Induces Apoptosis in Human Hepatoma-derived Cell Lines. J. Hepatol. 2002, 36, 660-671.
67. Moriwaki, H.; Yasuda, I.; Shiratori, Y.; Uematsu, T.; Okuno, M.; Muto, Y. Deletion of Serum Lectin-reactive α-Fetoprotein by Acyclic Retinoid: A Potent Biomarker in The Chemoprevention of Second Primary Hepatoma. Clin. Cancer Res. 1997, 3, 727-731.
68. Shiraki, K.; Takase, K.; Tameda, Y.; Hamada, M.; Kosaka, Y.; Nakano, T. A Clinical Study of Lectin-reactive α-Fetoprotein as An Early Indicator of Hepatocellular Carcinoma in The Follow-up of Cirrhotic Patients. Hepatology 1995, 22, 802-807.
69. Moriwaki, H.; Okuno, M.; Shiratori, Y.; Yasuda, I.; Muto, Y. In Frontiers in Hepatology. Progress in Hepatocellular Carcinoma Treatment: Clonal Deletion, A Novel Strategy of Cancer Control That Falls between Cancer Chemoprevention and Cancer Chemotherapy: A Clinical Experience in Liver Cancer; Okita, K., Ed.; Springer-Verlag: Tokyo, 2000, pp. 97-103.
70. Okuno, M.; Moriwaki, H.; Matsushima-Nishiwaki, R.; Sano, T.; Adachi, S.; Akita, K.; Kojima S. In Frontiers in Hepatology. Growth, Proliferation, and Apoptosis in Hepatocytes: Retinoid-induced Apoptosis in Hepatocellular Carcinoma: A Molecular Basis for "Clonal Deletion" Therapy; Okita, K., Ed.; Springer-Verlag: Tokyo, 2002, pp33-39.
71. Okuno, M.; Sano, T.; Matsushima-Nishiwaki, R.; Adachi, S.; Akita, K.; Okano, Y.; Kojima, S.; Moriwaki, H. Apoptosis Induction by Acyclic Retinoid: A Molecular Basis of 'Clonal Deletion' Therapy for Hepatocellular Carcinoma. Jpn. J. Clin. Oncol. 2001, 31, 358-362.
72. Yamada, Y.; Shidoji, Y.; Fukutomi, Y.; Ishikawa, T.; Kaneko, T.; Nakagama, H.; Imawari, M.; Moriwaki, H.; Muto, Y. Positive and Negative Regulations of Albumin Gene Expression by Retinoids in Human Hepatoma Cell Lines. Mol. Carcinog. 1994, 10, 151-158.
73. Oliverio, S.; Amendola, A.; DiSano, F.; Farrace, M.G.; Fésüs, L.; Nemes, Z.; Piredda, L.; Spinedi, A.; Piacentini, M. Tissue transglutaminase-dependent posttranslational modification of the retinoblastoma gene product in promonocytic cells undergoing apoptosis. Mol. Cell. Biol. 1997, 17, 6040-6048.
74. Oliverio, S.; Amendola, A.; Rodolfo, C.; Spinedi A.; Piacentini M. Inhibition of "tissue" transglutaminase increases cell survival by preventing apoptosis. J. Biol. Chem. 1999, 274, 34123-34128.
75. Nagy, L.; Thomazy, V. A.; Heyman, R. A.; Davies, P. J. A. Retinoid-induced Apoptosis in Normal and Neoplastic Tissues. Cell Death Different. 1998, 5, 11-19.
76. Adachi, S.; Moriwaki, H.; Muto, Y.; Yamada, Y.; Fukutomi, Y.; Shimazaki, M.; Okuno, M.; Ninomiya, M. Reduced Retinoid Content in Hepatocellular Carcinoma with Special Reference to Alcohol Consumption. Hepatology 1991, 14, 776-780.
77. Matsushima-Nishiwaki, R.; Shidoji, Y.; Nishiwaki, S.; Yamada. T.; Moriwaki, Y.; Muto, Y. Aberrant Metabolism of Retinoid X Receptor Proteins in Human Hepatocellular Carcinoma. Mol. Cell Endocrinol. 1996, 121, 179-190.
78. Matsushima-Nishiwaki, R.; Okuno, M.; Adachi, S.; Sano, T.; Akita, K.; Moriwaki, H.; Friedman, S. L.; Kojima, S. Phosphorylation of Retinoid X Receptor α at Serine 260 Impairs Its Metabolism and Function in Human Hepatocellular Carcinoma. Cancer Res. 2001, 61, 7675-7682.
79. Suzui, M.; Masuda, M.; Lim, J. T. E.; Albanese, C.; Pestell, R. G.; Weinstein, I. B. Growth Inhibition of Human Hepatoma Cells by Acyclic Retinoid Is Associated with Induction of p21 and Inhibition of Expression of Cyclin D1. Cancer Res. 2002, 62, 3997-4006.
80. Obora, A.; Shiratori, Y.; Okuno, M.; Adachi, S.; Takano, Y.; Matsushima-Nishiwaki, R.; Yasuda, I.; Yamada, Y.; Akita, K.; Sano, T.; Shimada, J.; Kojima, S.; Okano, Y.; Friedman, S.L.; Moriwaki, H. Synergistic Induction of Apoptosis by Acyclic Retinoid and Interferon-β in Human Hepatocelluar Carcinoma Cells. Hepatology 2002, 36, 1115-1124.
81. Adachi, S.; Okuno, M.; Matsushima-Nishiwaki, R.; Takano, Y.; Kojima, S.; Friedman, S.L.; Moriwaki, H.; Okano, Y. Phosphorylation of Retinoid X Receptor Suppresses Its Ubiquitination in Human Hepatocellular Carcinoma. Hepatology 2002, 35, 332-340.
82. Matsushima-Nishiwaki, R.; Okuno, M.; Takano, Y.; Kojima, S.; Friedman, S.L.; Moriwaki, H. Molecular mechanism for growth suppression of human hepatocellular carcinoma cells by acyclic retinoid. Carcinogenesis 2003, 24, 1353-1359.
83. Hong, W. K.; Lippman, S. M.; Hittelman, W. N.; Lotan, R. Retinoid Chemoprevention of Aerodigestive Cancer: from Basic Research to the Clinic. Clin. Cancer Res. 1995, 1, 677-686.
84. Lotan, R. Retinoids in Cancer Chemoprevention. FASEB J. 1996, 10, 1031-1039.
85. Lotan, R. Retinoids and Apoptosis: Implications for Cancer Chemoprevention and Therapy. J. Natl. Cancer Inst. 1995, 22, 1655-1657.